Availability, Usage, and Preferences of Estradiol and Progestogen Preparations for Puberty Induction from a Multicentral Perspective
Authors' conclusion
This study highlights global challenges in accessing suitable hormone preparations for female pubertal induction. In most countries, the lowest dose of the estradiol is 50 µg for patches and 2 mg for tablets. Appropriate low-dose 17β-estradiol tablets are much less available than low-dose patches. Our survey underscores the importance of adapting guidelines to local availability, and the need for improved accessibility to address these global disparities.
Study context
- Population
- Paediatric endocrinologists worldwide, surveyed on availability of oral/transdermal 17β-estradiol and progestogen preparations for pubertal induction in girls with hypogonadism; June 2020 to December 2022
- Participants
- 229 participants45 countries
- Outcome
- Current availability of oestrogen and progesterone preparations worldwide
Methodological detailsquestionnaire survey, multicentre, endorsed by the ESPE Turner Syndrome Working Group, SurveyMonkey survey disseminated via ESPE channels, direct outreach and conferences
- Questionnaire survey
- Multicentre
- Endorsed by the ESPE Turner Syndrome Working Group
- SurveyMonkey survey disseminated via ESPE channels, direct outreach and conferences
Main finding
As reported in the abstract
- Oral 17β-estradiol in adult dosage accessible
- 86.5%
- Transdermal 17β-estradiol in adult dosage accessible
- 84.3%
- Transdermal administration preferred
- 62.8%
- 50 μg patches available
- 32 countries
- 1 mg tablets available
- 65.8% countries
- 2 mg tablets available
- 71.1% countries
- 0.5 mg 17β-estradiol tablets available (respondents from 8 countries)
- 20%
- 14 μg/day patches available
- 3 countries
- 25 μg/day patches available
- 20 countries
- Oral progestogen available
- 96.0%
- Oral progestogen preferred
- 87.0%
- Transdermal progestogen usage
- 15.2%
Observational data: associations, not effects.
Original publication
Availability, Usage, and Preferences of Estradiol and Progestogen Preparations for Puberty Induction from a Multicentral Perspective. Horm Res Paediatr. Published 8 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →